PT  - JOURNAL ARTICLE
AU  - Lia D'Ambrosio
AU  - Rosella Centis
AU  - Giovanni Sotgiu
AU  - Emanuele Pontali
AU  - Antonio Spanevello
AU  - Giovanni Battista Migliori
TI  - New anti-tuberculosis drugs and regimens: 2015 update
AID  - 10.1183/23120541.00010-2015
DP  - 2015 May 01
TA  - ERJ Open Research
PG  - 00010-2015
VI  - 1
IP  - 1
4099  - http://openres.ersjournals.com/content/1/1/00010-2015.short
4100  - http://openres.ersjournals.com/content/1/1/00010-2015.full
SO  - erjor2015 May 01; 1
AB  - Over 480 000 cases of multidrug-resistant (MDR) tuberculosis (TB) occur every year globally, 9% of them being affected by extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis. The treatment of MDR/XDR-TB is unfortunately long, toxic and expensive, and the success rate largely unsatisfactory (<20% among cases with resistance patterns beyond XDR).The aim of this review is to summarise the available evidence-based updated international recommendations to manage MDR/XDR-TB, and to update the reader on the role of newly developed drugs (delamanid, bedaquiline and pretomanid) as well as repurposed drugs (linezolid and meropenem clavulanate, among others) used to treat these conditions within new regimens.A nonsystematic review based on historical trials results as well as on recent literature and World Health Organization (WHO) guidelines has been performed, with special focus on the approach to managing MDR/XDR-TB.The new, innovative global public health interventions, recently approved by WHO and known as the “End TB Strategy”, support the vision of a TB-free world with zero death, disease and suffering due to TB. Adequate, universally accessed treatment is a pre-requisite to reach TB elimination. New shorter, cheap, safe and effective anti-TB regimens are necessary to boost TB elimination.The new WHO post-2015 End TB Strategy will support the efforts that research on new drugs and regimens requires http://ow.ly/LnJER